SHARPE
Reported results
- Net sales $80.9 million, up 6.9% YoY; Med Tech net sales $39.9 million, up 13.2%; Med Device net sales $41.0 million, up 1.4%
- GAAP gross margin 59.4%, up 410 basis points from prior year; tariff refunds of $1.2 million received during quarter
- GAAP net loss $7.1 million, or loss per share of $0.17, compared to net loss $10.9 million or loss per share $0.26 in prior year quarter
- Non-GAAP adjusted net loss $1.8 million, or adjusted loss per share of $0.04, compared to adjusted net loss $4.2 million or adjusted loss per share $0.10 in prior year quarter
- Non-GAAP adjusted EBITDA $5.0 million, compared to $2.2 million in prior year quarter
- Cash at August 31, 2026 was $34.0 million with debt-free balance sheet; operating cash used $15.3 million in quarter
Guidance
- FY2027 net sales guidance: $336.0M – $341.0M
- FY2027 Med Tech net sales growth guidance: 12% – 15%
- FY2027 Med Device net sales growth guidance: Flat
- FY2027 gross margin guidance: 54% – 55%
- FY2027 non-GAAP adjusted EBITDA guidance: $13.0M – $16.0M
- FY2027 non-GAAP adjusted EPS guidance: ($0.29) – ($0.24)
Notes
CEO transition: Eric Honroth appointed President and CEO effective November 2, 2026, succeeding Jim Clemmer. Company received FDA IDE approval for RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia treatment. Guidance was reiterated as of October 8, 2026. Company expects gross margin to be lower in second half of FY2027 than in first half. Tariff impact in FY2027 expected to be similar to FY2026 (excluding refunds).
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-08 (8-K, Item 2.02). Read the original filing on sec.gov.